Gene Therapy Blog
AMT fails to get marketing authorization for Glybera
- Details
- Category: Editorial Team
- Published on Tuesday, 01 November 2011 10:45
- Written by Administrator
- Hits: 986
Gene therapy suffered another blow, when Dutch biotech company Amsterdam Molecular Therapeutics, AMT, got another negative opinion for it's lead drug Glybera. The opinion was already a second for Glybera, since the company got first negative opinion in July 2011 and asked for re-examination from EMA.
Interestingly, this time the company got a positive opinion from CAT, Committee of Advanced Therapies, which might indicate that the product was deemed safe and effective, but CHMP, The Committee for Medicinal Products for Human Use, voted to yield a negative decision.
Read more: AMT fails to get marketing authorization for Glybera
ARK fails to get MAA for Cerepro
- Details
- Category: Editorial Team
- Published on Friday, 18 December 2009 00:00
- Written by Administrator
- Hits: 3092
Today Ark released the negative opinion of EMEA for it's crucial Cerepro- drug.
"The main underlying objection from the regulator which had not been resolved concerns specifically whether or not patients treated with Cerepro® might for some reason, have been left longer by surgeons prior to re-intervention than those who did not receive Cerepro®. As time to re-intervention is the main efficacy measure in the primary endpoint, the assessors determined that they could not recommend approval based on the data presented by Ark so far. The CHMP has thus adopted a negative opinion as Ark had not at that point in time provided trial evidence beyond doubt that Cerepro® has demonstrated adequate efficacy."
Targeted Genetics buys more time - Genzyme gets IP
- Details
- Category: Editorial Team
- Published on Tuesday, 15 September 2009 00:00
- Written by Administrator
- Hits: 2543
Targeted Genetics Corporation (NASDAQ: TGEN) today announced the sale to Genzyme Corporation of certain assets, including manufacturing technologies and other adeno-associated viral (AAV) vector technology, for up to $7 million in cash. The purchased assets consist primarily of patents, know-how and manufacturing-related equipment. Genzyme also received a license to use certain technology and materials necessary for manufacturing AAV vectors.
Read more: Targeted Genetics buys more time - Genzyme gets IP
More Articles...
Menu
User Login
Follow Us On
